- Home
- ESLA vs SNTI Comparison
ESLA vs SNTI Comparison
Compare ESLA & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESLA
- SNTI
- Stock Information
- Founded
- ESLA 2021
- SNTI 2016
- Country
- ESLA United States
- SNTI United States
- Employees
- ESLA N/A
- SNTI N/A
- Industry
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- ESLA Health Care
- SNTI Health Care
- Exchange
- ESLA Nasdaq
- SNTI Nasdaq
- Market Cap
- ESLA 35.9M
- SNTI 39.6M
- IPO Year
- ESLA N/A
- SNTI N/A
- Fundamental
- Price
- ESLA $1.05
- SNTI $1.36
- Analyst Decision
- ESLA Strong Buy
- SNTI Strong Buy
- Analyst Count
- ESLA 1
- SNTI 2
- Target Price
- ESLA $16.00
- SNTI $8.50
- AVG Volume (30 Days)
- ESLA 25.2K
- SNTI 123.0K
- Earning Date
- ESLA 08-12-2025
- SNTI 11-13-2025
- Dividend Yield
- ESLA N/A
- SNTI N/A
- EPS Growth
- ESLA N/A
- SNTI N/A
- EPS
- ESLA N/A
- SNTI N/A
- Revenue
- ESLA N/A
- SNTI N/A
- Revenue This Year
- ESLA N/A
- SNTI N/A
- Revenue Next Year
- ESLA N/A
- SNTI $150.00
- P/E Ratio
- ESLA N/A
- SNTI N/A
- Revenue Growth
- ESLA N/A
- SNTI N/A
- 52 Week Low
- ESLA $0.63
- SNTI $1.26
- 52 Week High
- ESLA $1.78
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- ESLA 61.31
- SNTI 34.87
- Support Level
- ESLA $0.99
- SNTI $1.38
- Resistance Level
- ESLA $1.08
- SNTI $1.39
- Average True Range (ATR)
- ESLA 0.07
- SNTI 0.08
- MACD
- ESLA 0.00
- SNTI 0.01
- Stochastic Oscillator
- ESLA 76.63
- SNTI 28.57
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.